Clinical, Cosmetic and Investigational Dermatology (May 2019)
Spotlight on brodalumab in the treatment of plaque psoriasis: the evidence to date
Abstract
M Galluzzo,* S D’Adamio,* A Massaro, A Piccolo, L Bianchi, M TalamontiDermatology, Department of “Medicina dei Sistemi”, University of Rome Tor Vergata, Rome, Italy *These authors contributed equally to this work Abstract: The IL-17/IL-23 axis is now understood to influence psoriasis, and the development of novel IL-17 inhibitor medications marks a sea change in the treatment of psoriasis. Brodalumab is a recombinant, fully human immunoglobulin IgG2 monoclonal antibody specifically targeted against IL-17RA. This article discusses the mechanism of action and the efficacy and safety profile of brodalumab presented in the literature. Brodalumab, the latest approved anti-IL-17-class medication, is the only one that exerts its effects on IL-17C as well as on IL-17A and IL-17F, blocking the shared IL-17 receptor A. In this sense, considering the recent evidence, brodalumab could have beneficial effects not only on psoriasis, but also on atopic dermatitis. It could also serve as a therapeutic alternative in patients who develop paradoxical eczematous reactions or atopic-like dermatitis during treatment with other anti-IL-17A (secukinumab, ixekizumab).Keywords: psoriasis, biologics, anti-IL17RA, brodalumab, PASI100, atopic dermatitis
